alexa The Potential Role of Donepezil for the Treatment of De
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

The Potential Role of Donepezil for the Treatment of Dementia w ith Lewy Bodies

Norifumi Tsuno*

Department of Neuropsychiatry, Faculty of medicine, Kagawa University, Kagawa, Japan

Corresponding Author:
Norifumi Tsuno
Department of Neuropsychiatry, Faculty of medicine
Kagawa University 1750-1, Ikenobe, Miki-cho
Kita-gun, Kagawa 761-0793, Japan
Tel: 81-87-891-2166
Fax: 81-87-891-2168
E-mail: [email protected]

Received date: January 24, 2016; Accepted date: February 25, 2016; Published date: March 02, 2016

Citation: Tsuno N (2016) The Potential Role of Donepezil for the Treatment of Dementia with Lewy Bodies. J Alzheimers Dis Parkinsonism 6:214. doi:10.4172/2161-0460.1000214

Copyright: © 2016 Tsuno N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Dementia with Lewy bodies (DLB) is a common form of dementia in the elderly and constitutes the second largest group of patients with degenerative dementia. To date, on the one hand, four cholinesterase inhibitors (ChEIs) have been approved for the treatment of Alzheimer’s disease (AD). On the other hand, there are no drug for approved for the treatment of DLB. However clinical benefits and good tolerability have recently been reported in several clinical trials of cholinesterase inhibitors (ChEIs), particularly donepezil. This review describes various aspects of donepezil, including basic pharmacology and pharmacokinetics, with the primary focus on the clinical work.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version